by Katy Spink & Andrew Steinsapir

With the 2017 FDA approvals and launches of the first gene-modified cell and pure-play gene therapy products to gain licensure in the United States, increasing attention has been paid to the high cost of …

Experts from North American and European organisations are also supporting the trade mission. Anthony Davies, Ph.D., CEO of Dark Horse Consulting added, “As the first and only global consulting practice focused on CMC for cell and gene therapy, Dark Horse …

Product approvals and a regulatory focus on regenerative medicines has made 2017 a breakthrough year for cell and gene therapies, say consultants.